Table 3.

Targeting the NLRP3 inflammasome: a list of currently FDA approved therapies or preclinical compounds that target the NLRP3 inflammasome, either through inhibition of transcriptional priming, inflammasome assembly, or NLRP3 activated cytokines. These treatments may be leveraged to target neuroinflammatory states in patients with major depressive disorder or other psychiatric disorders.

Current Immune Treatments	Target (Effect)	Type (Mimicked Protein)
Anakirna	IL-1R (Antagonist)	IL-1β
Rilonacept	IL-1β (Trap)	IL-1R/IgG1
Pegilodecakin	IL-10R (Agonist)	PEGylated IL-10
Mifepristone	GR (Antagonist)	Prostagladin Analogue
MCC-950	NLRP3 (Inhibits Assembly)	Small Molecule Compound
Avonex	IFN-βR (Agonist)	Interferon Beta-1
Etanercept	TNF-α (Trap)	TNFR-II/IgG1 Fc
G5	Deubiquitinases (Inhibitor)	Small Molecule Compound
Azeliragon	RAGE (Inhibitor)	Small Molecule Compound
Ibrutinib	BTK (Inhibitor)	Small Molecule Compound
TAK-242	TLR-4 (Inhibitor)	Small Molecule Compound
Oxaborine Derivatives	NLRP3 (Inhibits Assembly)	Small Molecule Compound